Advertisement

Topics

Oyster Point Pharma, Inc. Company Profile

20:23 EDT 18th July 2018 | BioPortfolio

Based in Princeton, New Jersey, Oyster Point is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop, and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is on developing innovative therapeutics to treat the signs and symptoms of Dry Eye Disease by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via nasal spray and are currently in Phase 2 trials for the treatment of Dry Eye Disease.


News Articles [864 Associated News Articles listed on BioPortfolio]

Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic

Spun out from Oculeve in tandem with that company’s acquisition by Allergan, Oyster Point hopes to develop a nasal spray...   

Oyster Point's nasal spray meets in Phase IIb for dry eye

Global and China Calcium Carbonate from Oyster Shell Market Research by Company, Type Application 20132025 [Report Updated: 15122017] Prices from USD $2000

SummaryCalcium Carbonate from Oyster Shell means that the calcium carbonate is produced from oyster shell. Oyster shells are derived from marine source, consisting of Calcium, Magnesium, Silica which ...

Oyster Point Pharma Announces FDA Clearance of Investigational New Drug Application for the Treatment of Dry Eye Disease

Second Product Candidate to Receive an IND Clearance in Less Than 12 Months Oyster Point Pharma, Inc., a clinical-stage pharmaceutical company, today announced that the...

Oyster Point Pharma Announces Positive Results from Phase 2 Clinical Trial of the Company’s Investigational Treatment for Dry Eye Disease

OC-02, Delivered in a Nasal Spray, Meets Primary Endpoints of Significant Improvement in Both Signs and Symptoms of Dry Eye Disease Oyster Point Pharma, Inc., today ...

#jobs #lifescience Process Engineer Associate

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Process Engineer Associate .PA-West Point, West Point, Pennsylvania Skills : ...

8 Things That Could Go Wrong With Your Pharma Marketing Campaign

Author: Marc Benjamin, CEO, Convergence Point Media Pharma marketing can sometimes feel like a thankless job, with the web of overlapping indications, “second plus”-line treatments, FDA regulatio...

#jobs #lifescience Pharmaceutical Technical Writer

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pharmaceutical Technical Writer .PA-West Point, 1 year contract A large pharm...

PubMed Articles [566 Associated PubMed Articles listed on BioPortfolio]

Influence of Thermal Treatment on the Characteristics of Major Oyster Allergen Cra g 1 (Tropomyosin).

Shellfish, including oysters, often cause allergic reactions in adults. Thermal treatment is one of the most common technologies to deal with seafood, which may affect biological properties. The aim o...

Temperature modulate disease susceptibility of the Pacific oyster Crassostrea gigas and virulence of the Ostreid herpesvirus type 1.

Temperature triggers marine diseases by changing host susceptibility and pathogen virulence. Oyster mortalities associated with the Ostreid herpesvirus type 1 (OsHV-1) have occurred seasonally in Euro...

Different residue behaviors of four pesticides in mushroom using two different application methods.

Pesticide residue in mushrooms is less known. In this study, the risks of beta-cypermethrin, pyriproxyfen, avermectin, and diflubenzuron in oyster and shiitake mushrooms were evaluated using two diffe...

Antiviral Defense and Innate Immune Memory in the Oyster.

The Pacific oyster,, is becoming a valuable model for investigating antiviral defense in the Lophotrochozoa superphylum. In the past five years, improvements to laboratory-based experimental infection...

A DM9-containing protein from oyster Crassostrea gigas (CgDM9CP-2) serves as a multipotent pattern recognition receptor.

DM9 is a novel protein domain with unknown function originally discovered in Drosophila melanogaster. Recently, a protein harboring DM9 repeats was identified as mannose-specific lectin (CgCGL1, renam...

Clinical Trials [1146 Associated Clinical Trials listed on BioPortfolio]

Antihyperlipidemic Effects of Oyster Mushrooms

The primary goal of this study is to evaluate the short-term safety and potential efficacy of oyster mushrooms (Pleurotus ostreatus) for treatment of hyperlipidemia in HIV-infected patient...

Crassostrea Gigas for Liver Health

This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal. A total of 96 pa...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Companies [1236 Associated Companies listed on BioPortfolio]

Oyster Point Pharma, Inc.

Based in Princeton, New Jersey, Oyster Point is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop, and commercialize novel therapies to treat di...

Pennsylvania Environmental Council

Covering a total distance of 20-30 miles in four to six hours, on foot and on bike, the Oyster Race is the ultimate urban adventure race taking teams of three to six people throug...

Monogram Biosciences, Inc.

Monogram is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics ...

diaDexus, Inc.

Founded in 1997 by SmithKline Beecham (now GlaxoSmithKline) and Incyte, diaDexus, Inc. is a privately held biotechnology company focused on discovering, developing, and commercializing novel, patent-p...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

More Information about "Oyster Point Pharma, Inc." on BioPortfolio

We have published hundreds of Oyster Point Pharma, Inc. news stories on BioPortfolio along with dozens of Oyster Point Pharma, Inc. Clinical Trials and PubMed Articles about Oyster Point Pharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oyster Point Pharma, Inc. Companies in our database. You can also find out about relevant Oyster Point Pharma, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record